Eli Lilly Enters Gene Therapy Collaboration with Profluent
Eli Lilly (LLY) has entered into a research collaboration with Profluent, a biotech company focused on AI-driven drug discovery, to develop and commercialize genetic medicines. The deal is valued at up to $2.25 billion. This partnership aims to leverage Profluent's AI capabilities in drug discovery alongside Eli Lilly's expertise in pharmaceuticals.
Tickers: $LLY
Topics: AI-driven drug discovery biotech Eli Lilly genetic medicines research collaboration